Compound library / Skin, hair & topicals / Skin / Anti-aging

GHK-Cu

Copper-binding peptide naturally found in the body, explored for skin remodeling, wound healing, and anti-inflammatory effects.

CategorySkin / Anti-aging
Regulatory standingNo approved product cited
Typical routeSubcutaneous
Half-lifeShort, minutes
Common dose range1-2 mg/day (systemic) or topical formulations
Typical cycle length4-8 weeks

BioHack Track models GHK-Cu at a half-life of 0.1 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.

No approved product cited

No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.

Reconstitution

Reconstitute with bacteriostatic water for injectable form; topical creams pre-mixed.

Storage

Refrigerate.

Cautions

Topical use is more commonly studied than systemic injection.

Track GHK-Cu in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.

Others in Skin / Anti-aging

What the evidence says

Evidence Check asks 10 questions about every compound. For GHK-Cu it can answer 5 of them, from the papers we hold — graded by how strong the study design is, not by whether the findings are flattering. These are the same verdicts the app gives.

Some Clinical EvidenceSkin & collagen

Clinical trials in humans have looked at this.

  • Effects of topical copper tripeptide complex on CO2 laser-resurfaced skinRandomized Controlled Trial · Arch Facial Plast Surg · 2006 · PMID 16847171
  • Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospectiveReview · Bioimpacts · 2025 · PMID 39963574
  • Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?Review · Molecules · 2025 · PMID 39795193
Insufficient EvidenceCognition

Only reviews or early work — not enough to say either way.

  • The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive healthReview · Oxid Med Cell Longev · 2012 · PMID 22666519
Insufficient EvidenceInflammation

Only reviews or early work — not enough to say either way.

  • The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive healthReview · Oxid Med Cell Longev · 2012 · PMID 22666519
Insufficient EvidenceLongevity

Only reviews or early work — not enough to say either way.

  • Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?Review · Molecules · 2025 · PMID 39795193
  • The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive healthReview · Oxid Med Cell Longev · 2012 · PMID 22666519
Insufficient EvidenceWound healing

Only reviews or early work — not enough to say either way.

  • The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive healthReview · Oxid Med Cell Longev · 2012 · PMID 22666519

Look up the research

These open a search of each database for GHK-Cu — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.

Work it out

Selected published studies

7 papers naming GHK-Cu in the title, drawn from PubMed and limited to reviews, meta-analyses and trials. Each was checked against PubMed’s own record for its title, journal and year. This is a starting point, not an evidence review — nothing here is offered as support for the dose range above, and the list is not exhaustive. See the editorial policy.

Where these figures come from

The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.

These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.

Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.

Published by Creative Images LLC · Last updated · Corrections: support